Repros gains on second Androxal Phase III

Repros Therapeutics Inc. (NASDAQ:RPRX) gained $1.52 (17%) to $10.48 on Friday after its Androxal enclomiphene met both primary endpoints in the Phase III ZA-304 trial to treat secondary hypogonadism, which measured the percent change in average sperm concentration from baseline and the percentage of patients who responded to therapy. The company reported similar results last month from the identical Phase III ZA-305 trial.

Repros plans to submit an NDA to FDA for Androxal to treat secondary hypogonadism by year end. ...